The Bio Report
Levine Media Group
The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.
Get every episode summarized
Each time The Bio Report publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Is this your show?
Claim it: a verified badge, every new episode summarised to your inbox, and first say over how it is presented here.
Episodes (1239)
Understanding the Challenges and Opportunities of Patient-Centric Outcomes
The Bio Report
How CellMax Hopes to Change the Diagnosis Cancer with Inexpensive Liquid Biopsy
The Bio Report
How Surveillance and Data Are Bringing Precision to the Treatment of Prostate Ca...
The Bio Report
Why Life Sciences M&A Should Heat up This Year
The Bio Report
The Outlook for Biotech in 2018
The Bio Report
The Year in Biotech and What to Watch in 2018
The Bio Report
The Year in Immuno-Oncology and What to Watch in 2018
The Bio Report
What the Approval of the First Digital Pill Means for the Future of Healthcare
The Bio Report
Why Public Health Systems Need to Be Better Prepared for Extreme Weather Events
The Bio Report
Former CDC Director Takes on World’s Leading Cause of Death
The Bio Report
How a Public-Private Consortium Is Revolutionizing Cancer Drug Discovery
The Bio Report
How Faulty Thinking Can Derail Life Sciences M&A Deals
The Bio Report
Targeting Drug-Resistant Bacteria with an Ancient Enemy
The Bio Report
A Bioelectronic Approach to Treating Autoimmune Diseases
The Bio Report
Harnessing Patient Data to Improve Drug Development Efficiency
The Bio Report
How Colorifix Is Trying to Turn the Textile Industry Green
The Bio Report
Targeting Patients as Sick as Dogs
The Bio Report
A Strategic Investor’s View of the Biotech Investment Landscape
The Bio Report
Bringing Gender Diversity into Biotech Boardrooms
The Bio Report
Why the FDA May Need to Rethink Its Approach to Gene and Cell Therapy
The Bio Report
VBL Targets Brain and other Cancers with Novel Immunotherapy
The Bio Report
What Will It Take to Transform Healthcare to a System Focused on Prediction and...
The Bio Report
Can a Direct Pitch to Patients Drive a Home Run for Obesity Drug
The Bio Report
Why Companies Across Industries Need to Develop a Bio Strategy
The Bio Report
Economist Argues Maximizing Shareholder Value Hurts Drug Innovation
The Bio Report
Partnership Drives Development of Antibiotic to Combat Resistant Gonorrhea
The Bio Report
CIRM-Funded Pipeline of Regenerative Therapies Advances
The Bio Report
Technology Allows Drugmakers to Tag and Authenticate Individual Pills
The Bio Report
Harnessing Mosquitoes to Fight the Spread of Infectious Disease
The Bio Report
Biotech Industry Moves Towards a Patent Cliff
The Bio Report
PvP Takes a Unique Approach to Treating an Autoimmune Disease
The Bio Report
Uncertainty Hangs over the Biotech Sector
The Bio Report
What Others Can Learn from COI’s Approach to Cost-Efficient Drug Development
The Bio Report
Dyadic Seek to Bring Disruptive Technology to Biomanufacturing
The Bio Report
Enlisting the Immune System in the Battle Against Alzheimer’s
The Bio Report
Overcoming the Delivery Challenges of Gene Therapy
The Bio Report
Brexit Sparks Battle to House the EMA
The Bio Report
New Safety Concerns Identified After FDA Approval of One in Three Drugs
The Bio Report
Why Climate Change Is a Public Health Concern
The Bio Report
Reflections on the Progress and Promise of Personalzied Medicines
The Bio Report
Curing Cancer with Math
The Bio Report
How Healthcare Consumer Find and Use Price Information
The Bio Report
Why Infectious Disease Represents a National Security Threat
The Bio Report
Recent Mumps Outbreaks Raise Question If New Vaccine Is Needed
The Bio Report
Proposed Legislation Would Weaken Genetic Privacy Protections
The Bio Report
How Biomarkers Can Alter the View of and Approach to Alzheimer’s Disease
The Bio Report
The Fight for Personalized Medicine Wages on Many Fronts
The Bio Report
Big Pharma and the Growth and Outlook for Orphan Drugs
The Bio Report
What the Recent Patent Ruling Means for the Future of Gene-Editing Technology
The Bio Report
Weighing What Limits Should Be Put on Gene Editing
The Bio Report